Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, single center, placebo-controlled, interventional study to evaluate the safety, tolerability, and pharmacokinetic profiles in healthy subjects compared to placebo

Trial Profile

A phase 1, single center, placebo-controlled, interventional study to evaluate the safety, tolerability, and pharmacokinetic profiles in healthy subjects compared to placebo

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs OLX-10010 (Primary) ; OLX-10010 (Primary)
  • Indications Hypertrophic scars
  • Focus Adverse reactions
  • Sponsors OliX Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2018 New source identified and integrated (NCT03569267).
    • 29 May 2018 According to an OliX Pharmaceuticals media release, company has received the Phase I clinical trial authorization (CTA) with OLX10010, from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK as of May 11, 2018.
    • 23 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top